Noble Financial Capital Markets acts as Sole U.S. Placement Agent of Cynapsus Therapeutics, Inc. (CTH.V and CYNAF) $25million CAN private placement
About Cynapsus Therapeutics, Inc. (CTH.V and CYNAF)
Cynapsus Therapeutics Inc., a specialty pharmaceutical company, is engaged in developing non-injectable drugs used to treat the symptoms of Parkinson's disease. Its lead drug candidate includes APL-130277, an easy-to-administer, fast-acting, and oral reformulation of an approved drug, such as apomorphine, an injection that is used to rescue patients from OFF episodes. The company was formerly known as Cannasat Therapeutics Inc. and changed its name to Cynapsus Therapeutics Inc. in April 2010. Cynapsus Therapeutics Inc. is headquartered in Toronto, Canada.
Healthcare Investment Banking Group
Shawn Titcomb
Managing Director
Head of Healthcare Merchant and Investment Banking
Direct: 561.998.5480
Cell: 561.706.3250
stitcomb@noblefcm.com
Andrew Daniels
Head of Equity Capital Markets
Direct: 561.997.8947
Cell: 516.317.7994
adaniels@noblefcm.com
About Noble Financial Capital Markets
Noble Financial Capital Markets was established in 1984 and is an equity research driven, full-service, investment and merchant banking boutique focused on healthcare, technology, media and emerging growth companies. The company has offices in Boston, Los Angeles, and Boca Raton. Members: FINRA, SIPC, MSRB